ICI combination therapies that inhibit the CTLA-4 and PD-1 signaling pathways have achieved remarkable efficacy in patients with HCC (ORR, 20.1–32%; mOS, 18.7–22.2 months; 36-month OS rate, 30.7–42%) [147–150]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.